About Deep Bio
Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, computational pathology, life sciences, and pharmacotherapeutics. Deep Bio envisions a suite of AI-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device) for the diagnosis and prognosis of multiple cancers. Deep Bio is actively engaged in the research space and participating in ongoing collaborations with top US medical centers.
‍
‍
About Deep Bio’s automated Gleason scoring AI
Deep Bio, announced recently that it has received Korea MFDS (Ministry of Food and Drug Safety) approval for DeepDx®-Prostate Pro, its deep learning-based software that assists the histopathological diagnosis of prostate cancer as a Class III medical device.
‍
DeepDx®-Prostate Pro analyzes WSIs (Whole Slide Images) of H&E (Hematoxylin & Eosin) stained prostate core needle biopsies and automatically classifies the histological severity of prostate cancer. Analysis results automatically generate Gleason grades and Gleason scores based on the Gleason grading system. If a tissue is not categorized by the Gleason grading system, the result will show as ‘No Grade.’

DeepDx®-Prostate Pro supports severity analysis of prostate cancer, demonstrated robust performance in evaluation studies, showing 98.7% concordance in grade group classification and 96.9% concordance in the “No grade” group classification compared with reference standard created by three pathologists. DeepDx®-Prostate Pro also demonstrated high agreement with the pathologists. When compared with the analysis of three pathologists, the software analysis recorded a kappa score of 0.713 and a quadratic-weighted kappa score of 0.922. In addition, the software improved workflows by greatly reducing time spent on analyses. While it took 550 minutes for a pathologist to analyze the WSIs of the entire biopsy samples (593 cases) using the current standard of care, the same pathologist completed analyses of the same cases in 364 minutes with the software, marking 33.8% decrease in diagnostic turnaround time.

Tae Yeoung Kwak, the CTO of Deep Bio said “Deep Bio’s AI technology for analyzing prostate cancer has gained a global reputation following presentation in international conferences and academic journals. In addition to a model for prostate needle biopsies, Deep Bio is currently developing diagnostic algorithms to analyze other prostate tissue types obtained by transurethral prostatectomy (TURP) and prostatectomy, as well as pathologic tissue analysis technology for various cancer types such as breast cancer and bladder cancer. Deep Bio will make every effort to commercialize these technologies in the near future to improve existing diagnostic workflows.”


Morphle Labs x Deep Bio
Deep Bio partners with us, Morphle Labs to provide pathologists access to a series of AI-based prostate-specific tissue image analysis solutions. The bundled product will bring digital pathology and AI at affordable price points.
‍
With this partnership, Deep Bio’s deep learning-based prostate cancer diagnosis support software DeepDx® Prostate will now be available to pathologists through our digital pathology platform. With our state-of-the-art scanners at a fraction of the cost compared to traditional, high-volume scanners, the collaboration is expected to accelerate the rate of digital pathology adoption and enable access to the latest AI technologies in cancer diagnoses across the globe.

“DeepDx® is a natural fit on top of Morphle’s CLIA friendly remote microscopy workflow deployed across India and USA. We have observed latent demand from uropathology practices of all sizes across the globe. With this partnership, we are super-excited to offer this comprehensive solution going ahead for uropathologists” commented Rohit Hiwale, the CEO and founder of Morphle Labs.


Would you also like to share your AI alogrithms through our App Store? Get in touch with us below!